Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Bristol Myers"


9 mentions found


The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents. Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs. Amgen first sued Regeneron and Sanofi in 2014 over their rival drug Praluent, which works by a similar mechanism as Repatha. Thousand Oaks, California-based Amgen sold more than $1.1 billion worth of Repatha worldwide last year. Regeneron sold $170 million worth of Praluent in the United States last year, and Sanofi sold over $200 million worth in the rest of the world.
"I do think there is a possibility we see launch prices go up," she said. Reuters GraphicsPorter, who championed inflation-based caps on drug prices, is calling for additional national legislation to link launch prices to how well a drug works. The report found that the average launch price of a self-administered cancer drug, after adjusting for inflation, rose by nearly 26% to $238,000 between 2017 and 2021. By 2022, six out of the eight newly-launched oral cancer drugs had prices over $200,000 per year. Based on current trends, the report calculated that by 2026, when Medicare will first be able to negotiate drug prices, the average self-administered cancer drug launch price will be nearly $325,000 per year and over $525,000 for pills and biologics.
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBristol Myers Squibb CEO: We are on track to continue delivering growthBristol Myers Squibb CEO Dr. Giovanni Caforio joins CNBC's 'Squawk on the Street' to discuss the company's third-quarter earnings report.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Bristol Myers Squibb CEO Dr. Giovanni CaforioBristol Myers Squibb CEO Dr. Giovanni Caforio joins CNBC's 'Squawk on the Street' to discuss the company's third-quarter earnings report. Caforio also breaks down the company's portfolio of cardiovascular drugs, including heavyweight Eliquis. "Internationally, business was impacted by exchange," Caforio tells CNBC.
Morning Bid: Consumer drain as banks gain
  + stars: | 2022-10-26 | by ( ) www.reuters.com   time to read: +5 min
Google's results in particular bode ill for Facebook parent Meta Platforms (META.O), especially reliant on advertising and reporting its results late on Wednesday. Consumer blues contrasted with bumper earnings from banks who are raking in huge windfalls from rising interest rates - direct cash injections from reserves they hold at central banks along with higher net interest margins and trading revenues flattered by volatile markets. read more read more read more read moreEuropean banks reporting this week matched Wall St counterparts on that score, raising conundrums for the European Central Bank meeting this week and Bank of England and U.S. Federal Reserve gatherings next week. They all plan further policy rate rises to rein in inflation - but this also involves direct transfers to their banks and potentially a drain on government finances. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Many of the country’s largest pharmaceutical companies, from Merck & Co. to Bristol Myers Squibb are under pressure to do deals right now because they are staring at huge patent cliffs for their top-selling drugs. For investors considering whether to buy into these companies, figuring out which management teams are going to make the right acquisitions is a bit of a crapshoot. It can be difficult to build a financial model for a company without knowing who it will acquire. Further uncertainty comes from the fact that many pharma acquisitions involve drugs still in development. So the next best thing can be to look at management’s acquisition track record.
"That said, the biggest drugs usually feature one, or best case two, of these attributes." Seven drugs on Meacham's list are already in the market, and have already hit the $10 billion or more benchmark. That means some of these drugs may be already hitting the end of their peak sales period. Meacham has previously said that one of the drugs in this bucket, Eli Lilly's tirzepatide, could be the first $100 billion drug . But many investors are hopeful about its potential as an obesity treatment .
Final Trades: Salesforce, Cheniere, Bristol Myers & more
  + stars: | 2022-09-22 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Salesforce, Cheniere, Bristol Myers & moreThe "Halftime Report" traders give their top picks to watch for the second half.
With a successor search underway, Werner Baumann is entering his last chapter as Bayer's CEO. Baumann told Insider he's more excited today about Bayer's future than several years ago. The exec wants Bayer to become a top 10 cancer player by 2030, and recently opened a Cambridge lab. CAMBRIDGE, Massachusetts — Within his first month as CEO of the German giant Bayer, Werner Baumann took a big, legacy-making swing. Baumann says Bayer's future is in oncologyWerner Baumann, right, CEO of Bayer, and Werner Wenning, chairman of the Supervisory Board of Bayer.
Total: 9